PL4482481T3 - Związki do zastosowania w leczeniu dystrofinopatii - Google Patents
Związki do zastosowania w leczeniu dystrofinopatiiInfo
- Publication number
- PL4482481T3 PL4482481T3 PL23705290.7T PL23705290T PL4482481T3 PL 4482481 T3 PL4482481 T3 PL 4482481T3 PL 23705290 T PL23705290 T PL 23705290T PL 4482481 T3 PL4482481 T3 PL 4482481T3
- Authority
- PL
- Poland
- Prior art keywords
- dystrophinopathy
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382147.1A EP4230196A1 (en) | 2022-02-21 | 2022-02-21 | Compounds for use in the treatment of dystrophinopathies |
| PCT/EP2023/054140 WO2023156645A1 (en) | 2022-02-21 | 2023-02-20 | Compounds for use in the treatment of dystrophinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4482481T3 true PL4482481T3 (pl) | 2026-03-23 |
Family
ID=80446433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23705290.7T PL4482481T3 (pl) | 2022-02-21 | 2023-02-20 | Związki do zastosowania w leczeniu dystrofinopatii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250152567A1 (pl) |
| EP (2) | EP4230196A1 (pl) |
| JP (1) | JP2025508761A (pl) |
| KR (1) | KR20240150792A (pl) |
| CN (1) | CN118973560A (pl) |
| AU (1) | AU2023222467A1 (pl) |
| CA (1) | CA3244747A1 (pl) |
| DK (1) | DK4482481T3 (pl) |
| ES (1) | ES3061083T3 (pl) |
| IL (1) | IL315130A (pl) |
| MX (1) | MX2024010235A (pl) |
| PL (1) | PL4482481T3 (pl) |
| PT (1) | PT4482481T (pl) |
| WO (1) | WO2023156645A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025072685A1 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3111517A (en) | 1959-01-06 | 1963-11-19 | Pfizer & Co C | Derivatives of 3, 4-dihydrobenzo-thiadiazine dioxides |
| BE637389A (pl) | 1962-09-13 | |||
| GB1063821A (en) | 1964-03-13 | 1967-03-30 | Vsesoiuzny Ni Sky Khim Farmats | Prednisone preparation |
| GB1101747A (en) | 1964-04-09 | 1968-01-31 | Sterwin Ag | Salicylamide derivatives |
| DE1270544B (de) | 1965-06-19 | 1968-06-20 | Beiersdorf Ag | 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung |
| GB1176266A (en) | 1967-07-31 | 1970-01-01 | Kyowa Hakko Kogyo Kk | Process for Producing L-Citrulline |
| IT1044222B (it) | 1972-05-23 | 1980-03-20 | Zambeletti Spa L | Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata |
| IT1088554B (it) | 1977-11-17 | 1985-06-10 | F I D I A Spa | Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina |
| DE3069496D1 (de) | 1979-06-28 | 1984-11-29 | Takeda Chemical Industries Ltd | 2,3-dialkoxy-1,4-quinone derivatives; method of producing 1,4-quinone derivatives |
| US4749649A (en) | 1983-05-16 | 1988-06-07 | The Upjohn Company | Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen |
| DE3900261A1 (de) | 1988-05-31 | 1989-12-07 | Bayer Ag | Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate |
| US5332840A (en) | 1993-05-27 | 1994-07-26 | Bristol-Myers Squibb Company | Method for preparing a benzaldehyde intermediate |
| JP3559045B2 (ja) | 1994-06-10 | 2004-08-25 | ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク | 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体 |
| DE19529612A1 (de) | 1995-08-11 | 1997-02-13 | Merck Patent Gmbh | Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate |
| JP4016070B2 (ja) | 1995-12-13 | 2007-12-05 | サノフイ−アベンテイス・エツセ・ピー・アー | （１１β，１６β）―２１―（アセチルオキシ）―１１―ヒドロキシ―２’―メチル―５’Ｈ―プレグナ―１，４―ジエノ［１７，１６―Ｄ］オキサゾール―３，２０―ジオンの製造 |
| US5968826A (en) | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| EP2097095B1 (en) | 2006-11-29 | 2016-01-27 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| ES2564454T3 (es) | 2009-03-09 | 2016-03-22 | Taiho Pharmaceutical Co., Ltd. | Compuesto de piperazina que puede inhibir la prostaglandina D sintasa |
| EP2556083A4 (en) | 2010-04-05 | 2013-12-04 | Validus Biopharma Inc | NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT |
| CN105949260B (zh) | 2010-10-20 | 2017-10-31 | 泰国研究基金会 | 具有植物生长促进活性的脱皮素类似物 |
| SMT201800019T1 (it) | 2010-11-18 | 2018-03-08 | Technion Res & Dev Foundation | Amminoglicosidi e relativi usi nel trattamento di malattie genetiche |
| CN106913860A (zh) | 2011-09-29 | 2017-07-04 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| US9884076B2 (en) | 2012-06-05 | 2018-02-06 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| JP2016505627A (ja) | 2013-01-15 | 2016-02-25 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 治療剤、組成物、および血糖コントロールのための方法 |
| JP6411375B2 (ja) | 2013-01-26 | 2018-10-24 | スファエラ ファーマ プライベート リミテッド | カテキンの新規合成手法 |
| MX388221B (es) | 2013-04-20 | 2025-03-19 | Res Institute At Nationwide Children´S Hospital | ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2. |
| ZA201407536B (en) | 2013-10-21 | 2017-09-27 | Ems Sa | Parenteral pharmaceutical composition containing cosyntropin |
| MX373052B (es) | 2014-06-17 | 2020-05-11 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido. |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| WO2016059507A1 (en) | 2014-10-13 | 2016-04-21 | Kamavarapu Sarath Kumar | Improved process for the preparation of high pure metformine |
| IL258005B2 (en) | 2015-09-17 | 2025-01-01 | Res Inst Nationwide Childrens Hospital | Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2 |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| CA2971303C (en) | 2016-06-21 | 2026-03-03 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| KR102523522B1 (ko) | 2016-06-30 | 2023-04-20 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| JP7336769B2 (ja) | 2017-04-19 | 2023-09-01 | シーダーズ―シナイ メディカル センター | 骨格筋ジストロフィーを治療する方法及び組成物 |
| WO2019079386A1 (en) | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| IT201900003281A1 (it) | 2019-03-06 | 2020-09-06 | Chemi Spa | Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| TWI908746B (zh) | 2019-11-28 | 2025-12-21 | 美商銳進科斯生物股份有限公司 | 微小肌縮蛋白基因療法之構築體及其用途 |
| WO2021231630A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
-
2022
- 2022-02-21 EP EP22382147.1A patent/EP4230196A1/en not_active Withdrawn
-
2023
- 2023-02-20 AU AU2023222467A patent/AU2023222467A1/en active Pending
- 2023-02-20 MX MX2024010235A patent/MX2024010235A/es unknown
- 2023-02-20 PT PT237052907T patent/PT4482481T/pt unknown
- 2023-02-20 CA CA3244747A patent/CA3244747A1/en active Pending
- 2023-02-20 KR KR1020247031001A patent/KR20240150792A/ko active Pending
- 2023-02-20 EP EP23705290.7A patent/EP4482481B1/en active Active
- 2023-02-20 DK DK23705290.7T patent/DK4482481T3/da active
- 2023-02-20 PL PL23705290.7T patent/PL4482481T3/pl unknown
- 2023-02-20 IL IL315130A patent/IL315130A/en unknown
- 2023-02-20 ES ES23705290T patent/ES3061083T3/es active Active
- 2023-02-20 WO PCT/EP2023/054140 patent/WO2023156645A1/en not_active Ceased
- 2023-02-20 CN CN202380032731.1A patent/CN118973560A/zh active Pending
- 2023-02-20 JP JP2024548769A patent/JP2025508761A/ja active Pending
- 2023-02-20 US US18/839,918 patent/US20250152567A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118973560A (zh) | 2024-11-15 |
| EP4230196A1 (en) | 2023-08-23 |
| CA3244747A1 (en) | 2023-08-24 |
| EP4482481B1 (en) | 2025-11-12 |
| DK4482481T3 (da) | 2026-02-02 |
| PT4482481T (pt) | 2026-02-16 |
| WO2023156645A1 (en) | 2023-08-24 |
| EP4482481A1 (en) | 2025-01-01 |
| MX2024010235A (es) | 2024-09-19 |
| IL315130A (en) | 2024-10-01 |
| JP2025508761A (ja) | 2025-04-10 |
| US20250152567A1 (en) | 2025-05-15 |
| KR20240150792A (ko) | 2024-10-16 |
| ES3061083T3 (en) | 2026-03-31 |
| AU2023222467A1 (en) | 2024-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE063145T2 (hu) | Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| EP4236831C0 (en) | BODY LIGHT THROMBUS TREATMENT SYSTEM | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| HUE058931T2 (hu) | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| EP4570877A4 (en) | SURFACE TREATMENT AGENT | |
| EP4509551A4 (en) | SURFACE TREATMENT AGENT | |
| EP3471717A4 (en) | TREATMENT OF PLATE CELL CARCINOMAS WITH ERK INHIBITORS | |
| EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| PL3773589T3 (pl) | Inhibitor RET do stosowania w leczeniu raka ze zmianą RET | |
| EP3947460A4 (en) | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| IL311922A (en) | Heterocyclic compounds for use in the treatment of cancer | |
| EP4299677A4 (en) | SURFACE TREATMENT AGENT | |
| PL4161528T3 (pl) | Kombinacja ruksolitynibu z incb057643 do stosowania w leczeniu nowotworów mieloproliferacyjnych | |
| PL4482481T3 (pl) | Związki do zastosowania w leczeniu dystrofinopatii | |
| PL4182311T3 (pl) | Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych | |
| EP4269468A4 (en) | SURFACE TREATMENT AGENT | |
| EP4242249A4 (en) | SURFACE TREATMENT AGENT | |
| SI3934653T1 (sl) | Azelastin za protivirusno zdravljenje | |
| MA54941A (fr) | Polythérapie pour le traitement de malignités des cellules b | |
| EP4328256A4 (en) | SURFACE TREATMENT AGENT | |
| PL4146225T3 (pl) | Związki metylotioniniowe do zastosowania w leczeniu hipoksemii |